Immunoglobulin A nephropathy (IgAN) is currently the most prevalent primary glomerular disease worldwide, with a particularly high incidence in the Asian population. Clinical studies have demonstrated that approximately 20%–40% of IgAN patients may progress to end-stage renal disease (ESRD). Therefore, in-depth investigations into the risk assessment of IgAN, its early diagnosis and prognostic prediction, the elucidation of its pathogenesis, and the optimization of therapeutic strategies—all aimed at improving patients' long-term prognosis—hold significant clinical value and scientific significance.
Ren et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: